Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006.
New Zealand introduced a new outer membrane vesicle vaccine in 2004 to combat an epidemic of group B meningococcal disease. An Independent Safety Monitoring Board oversaw intensive safety monitoring, which included hospital surveillance, health professional reporting (passive and active) and mortality monitoring. With over three million doses administered to individuals aged under 20 years, the monitoring results provide consistent evidence supporting the vaccine's safety.
McNicholas
Anne
A
Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand. anne_mcnicholas@moh.govt.nz
Galloway
Yvonne
Y
Stehr-Green
Paul
P
Reid
Stewart
S
Radke
Sarah
S
Sexton
Kerry
K
Kieft
Charlotte
C
Macdonald
Claire
C
Neutze
Jocelyn
J
Drake
Ross
R
Isaac
Dorothy
D
O'Donnell
Mary
M
Tatley
Michael
M
Oster
Philipp
P
O'Hallahan
Jane
J
D006801:Humans; D007115:Immunization Schedule; D008585:Meningitis, Meningococcal / Q000453:epidemiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D009520:New Zealand / Q000453:epidemiology; D011358:Product Surveillance, Postmarketing / Q000379:methods* / Q000639:trends; D016896:Treatment Outcome
D022401:Meningococcal Vaccines